Compatibility of drug infusions in the NICU

Archives of Disease in Childhood

Volumn 95, Issue 9, 2010, Pages 745-748

  Kalikstad, Betty ^a,b   Skjerdal, Åse ^c   Hansen, Thor Willy Ruud ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

INFUSION FLUID; LIPID EMULSION; SERUM ALBUMIN;

ARTICLE; DRUG INFUSION; HUMAN; NEWBORN INTENSIVE CARE; PH; PRIORITY JOURNAL; QUALITY CONTROL; DEVICES; DRUG INTERACTION; DRUG STABILITY; INTRAVENOUS DRUG ADMINISTRATION; NEWBORN; OFF LABEL DRUG USE; PARENTERAL NUTRITION;

DRUG INTERACTIONS; DRUG STABILITY; FAT EMULSIONS, INTRAVENOUS; HUMANS; HYDROGEN-ION CONCENTRATION; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS, NEONATAL; OFF-LABEL USE; PARENTERAL NUTRITION; SERUM ALBUMIN;

EID: 77955718873     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2009.174268     Document Type: Article

References (30)

1. Choonara I, Conroy S. Unlicensed and off-label drug use in children: implications for safety. Drug Saf 2002;25:1-5. (Pubitemid 34208327)
2. Neubert A, Dormann H, Weiss J, et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf 2004;27:1059-67. (Pubitemid 39487067)
3. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157-67.
4. Blake MJ, Castro L, Leeder JS, et al. Ontogeny of drug metabolizing enzymes in the neonate. Semin Fetal Neonatal Med 2005;10:123-38. (Pubitemid 40215540)
5. Avenel S, Bomkratz A, Dassieu G, et al. The incidence of prescriptions without marketing product license in a neonatal intensive care unit. Arch Pediatr 2000;7:143-7. (Pubitemid 30091004)
6. O'Donnell CP, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics 2002;110:e52.
7. Conroy S. Unlicensed and off-label drug use: issues and recommendations. Paediatr Drugs 2002;4:353-9.
8. Conroy S, McIntyre J, Choonara I. Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonatal Ed 1999;80:F142-4; discussion F144-5.
9. Shirkey H. Therapeutic orphans. Pediatrics 1999;104:583-4.
10. Shirkey HC. Therapeutic orphans - everybody's business. Ann Pharmacother 2006;40:1174.
11. Turner S, Nunn AJ, Fielding K, et al. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999;88:965-8. (Pubitemid 29448261)
12. Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf 2006;5:703-18. (Pubitemid 44322888)
13. Cheng K, Masters S, Stephenson T, et al. Identification of suspected fatal adverse drug reactions by paediatricians: a UK surveillance study. Arch Dis Child 2008;93:609-11. (Pubitemid 352030085)
14. Clarkson A, Choonara I. Surveillance for fatal suspected adverse drug reactions in the UK. Arch Dis Child 2002;87:462-6.
15. Gupta A, Waldhauser LK. Adverse drug reactions from birth to early childhood. Pediatr Clin North Am 1997;44:79-92. (Pubitemid 27102457)
16. Sharek PJ, Horbar JD, Mason W, et al. Adverse events in the neonatal intensive care unit: development, testing, and findings of an NICU-focused trigger tool to identify harm in North American NICUs. Pediatrics 2006;118:1332-40. (Pubitemid 46393776)
17. Kohut J 3rd, Trissel LA, Leissing NC. Don't ignore details of drug-compatibility reports. Am J Health Syst Pharm 1996;53:2339.
18. Trissel LA. Handbook on injectable drugs. 15th edn. Bethesda, Maryland, USA: American Society of Health-System Pharmacists, 2009.
19. Bhatt DR, Reber DJ, Wirtschafter DD, eds. Neonatal drug formulary. 4th edn. Los Angeles, USA: N.D.F., 1997.
20. Young TE, Mangum B. Neofax. 26th edn. New York: Thomson Reuters, 2009.
21. Taketomo CK, Hodding JH, Kraus DM. Pediatric dosage handbook. 13th edn. Hudson, OH: Lexi-Comp, 2007.
22. Myhr K. Legemidler til intravenøs injeksjon. En håndbok. Stockholm: Ekotryck, 1997.
23. Sweetman SC. Martindale: the complete drug reference. 35th edn. London: The Pharmaceutical Press, 2007.
24. Micromedex Healthcare series: 1974-2002. Colorado, USA: Thomson, 2005.
25. King Guide to parenteral admixtures. Critical Care Y-site Compatibility Wall Chart, 2010.
26. Syringe driver drug compatibility chart. Dr Eileen Palmer. Palliative Care syringe driver pack 4 Dr Eileen Palmer, 2009.
27. Gikic M, Di Paolo ER, Pannatier A, et al. Evaluation of physicochemical incompatibilities during parenteral drug administration in a paediatric intensive care unit. Pharm World Sci 2000;22:88-91.
28. Cuzzolin L, Zaccaron A, Fanos V. Unlicensed and off-label uses of drugs in paediatrics: a review of the literature. Fundam Clin Pharmacol 2003;17:125-31. (Pubitemid 36241462)
29. Duck S. Neonatal intravenous therapy. J Intraven Nurs 1997;20:121-8.
30. Bradley JS, Wassel RT, Lee L, et al. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics 2009;123:e609-13.